// App-Quantinova.ai

O3.2 : Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A

Researchers

Presenter

  • L. Seymour

Principal Investigators

  • A. Tinker

  • H. Hirte

  • N. Wagtmann

  • P. Dodion

Medical Centers

  • NCIC Clinical Trials Group, Kingston, ON, Canada

  • Innate Pharma, Marseille, France

Locations

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Hematological malignancies

  • Squamous cell carcinoma of the head and neck

  • Gynaecological cancer

  • Solid malignancies

  • Melanoma

Biomarkers

  • Natural Killer cells

  • Circulating tumor cells

  • Cluster of differentiation 8A

  • Carbohydrate antigen 125

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

  • Monalizumab

Outcome

  • N/A

Study Design

  • randomized

  • adaptive

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved